Lidoflazine

Chemical compound
  • C08EX01 (WHO)
Identifiers
  • 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
CAS Number
  • 3416-26-0 checkY
PubChem CID
  • 3926
ChemSpider
  • 3789 ☒N
UNII
  • J4ZHN3HBTE
KEGG
  • D04733 checkY
CompTox Dashboard (EPA)
  • DTXSID6045377 Edit this at Wikidata
ECHA InfoCard100.020.285 Edit this at WikidataChemical and physical dataFormulaC30H35F2N3OMolar mass491.627 g·mol−13D model (JSmol)
  • Interactive image
Melting point159 to 161 °C (318 to 322 °F)Solubility in waterAlmost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C)
  • CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
InChI
  • InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) ☒N
  • Key:ZBIAKUMOEKILTF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.

Physical properties

Solubility at room temperature

Extracted from[1]

Solvent 0.01

N

0.1

N

% pH % pH
Hydrochloric Acid 0.4 3.0 0.7 1.9
Tartaric Acid 0.3 3.1 1.0 2.5
Citric Acid 0.3 3.1 0.5 2.5
Lactic Acid 0.2 3.4 0.7 2.9
Acetic Acid 0.1 3.5 0.4 3.8

References

  1. ^ a b Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369.

Further reading

  • Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424. PMID 4222721. S2CID 31959581.
  • v
  • t
  • e
Ion channel modulators
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
  • GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
KCaTooltip Calcium-activated potassium channel
Blockers
  • BKCa-specific: Ethanol (alcohol)
  • GAL-021
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
  • Solnatide
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
  • See here instead.
LGICsTooltip Ligand gated ion channels
  • See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
  • v
  • t
  • e
Simple piperazines
(no additional rings)
Phenylpiperazines
Benzylpiperazines
Diphenylalkylpiperazines
(benzhydrylalkylpiperazines)
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclics
(piperazine attached via side chain)
Others/Uncategorized

[1]


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
  1. ^ Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB (June 2011). "Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.